Press Releases April 24, 2026 04:16 PM

Park Dental Partners Announces Dates for First Quarter 2026 Earnings Release and Conference Call

Park Dental Partners schedules Q1 2026 earnings release and investor conference call

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
PARK

Park Dental Partners, Inc. announced its upcoming first quarter 2026 earnings release scheduled for May 13, 2026, followed by a conference call on May 14, 2026, to discuss financial results. The company operates dental practices across multiple states and provides business support services to affiliated dental professionals.

Park Dental Partners Announces Dates for First Quarter 2026 Earnings Release and Conference Call
PARK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Park Dental Partners will release Q1 2026 financial results on May 13, 2026, after market close.
  • The company will hold a conference call on May 14, 2026, to discuss earnings results with investors.
  • As of end 2025, Park Dental Partners supports 214 affiliated doctors across 86 dental practice locations in three states with nearly 990 clinical support team members.

MINNEAPOLIS, April 24, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading dental resource organization, today announced that it will report its financial results for the quarter ended March 31, 2026 after market close on Wednesday, May 13, 2026.

The Company will host a conference call to discuss these results the next day on Thursday, May 14, 2026, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time).

A live webcast of the call will be accessible by registering using the link below or through the Investor Relations section of the Company’s website at https://investors.parkdentalpartners.com. A replay of the webcast will be available on the website for a limited time following the call.

Conference Call Details

  • Date: May 14, 2026
  • Time: 8:30 a.m. Eastern Time (7:30 a.m. Central Time)
  • Webcast: Link to Webcast Registration
  • Conference Call: Link to Conference Call Registration

About Park Dental Partners, Inc.

Park Dental Partners, Inc., and its subsidiaries (NASDAQ:PARK) is a dental resource organization that has put patients first since the establishment of its general dentistry group in 1972. The Company provides comprehensive business support services, including clinical team members, administrative personnel, facilities, and equipment, to its affiliated general and multi-specialty dental practices. As of year-end 2025, the Company had 214 affiliated doctors across 86 practice locations in three states. The Company’s clinical support team consisted of approximately 990 hygienists, dental assistants, and patient care coordinators that support affiliated doctors in operating their practices. The mission of our affiliated dental practices since inception has been to ensure patients enjoy the benefits of a lifetime of good oral health. This mission continues to be the driving force behind our organization today.

Park Dental Partners is based in Roseville, Minnesota. For more information, please visit parkdentalpartners.com.


Risks

  • Future earnings and financial performance may vary and impact stock performance following the report.
  • Dependence on affiliated dental practices and the broader dental care sector could influence operational results.
  • Economic or healthcare sector challenges impacting dental service demand and reimbursement rates may pose risks to the company.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026